Recent performance snapshot

Enliven Therapeutics (ELVN) has drawn investor attention after a sharp share price move, with the stock up about 167% year to date and roughly 153% over the past year.

That advance comes alongside a market value of about US$2.53b and recent 1 day and past month returns that were mixed, with the stock down 1.68% over the latest session but lower by about 6.12% over the month.

For Enliven Therapeutics, the pullback over the past month sits against a much stronger backdrop, with a 90 day share price return of 46.68% and a 3 year total shareholder return of 111.72%. This suggests momentum has cooled recently after a strong run.

If Enliven’s move has you looking at other cancer and biotech related opportunities tied to advanced computing, it could be a good moment to scan 34 healthcare AI stocks

With a market value near US$2.53b, no current revenue and a stock price well below the average analyst target, the key question is whether Enliven is mispriced today or if markets already reflect its future growth.

Preferred Price-to-Book of 5.6x: Is it justified?

The current picture suggests Enliven Therapeutics is priced well above book value, with a P/B of 5.6x compared with both peers and the broader US pharmaceuticals industry.

The price to book ratio compares the company’s market value with the net assets on its balance sheet. For early stage biopharma with no current revenue and ongoing losses, investors often focus on the value of the pipeline and R&D rather than today’s earnings, which can lead to higher P/B multiples.

In Enliven’s case, that 5.6x P/B sits above the US pharmaceuticals industry average of 2.3x and also above the peer average of 5.3x. This indicates investors are paying a premium even relative to similar companies. With no discounted cash flow estimate available, there is no fair ratio anchor that suggests the multiple could converge toward a different level. As a result, comparisons rest mainly on how it stacks up against sector and peer benchmarks.

Result: Price-to-book of 5.6x (OVERVALUED)

However, you also have to weigh the clinical and regulatory risk around ELVN-001 and ELVN-002, as well as the ongoing losses with no current revenue to offset them.

Next Steps

Mixed signals on price and risk can be hard to read, so act while interest is high and weigh the trade off yourself using 1 key reward and 5 important warning signs

Looking for more investment ideas?

Do not stop with a single stock. Broaden your watchlist with focused stock lists that highlight different ways to balance potential returns and risk.

• Target reliable cash generators by scanning companies with strong balance sheets and fundamentals using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot potential mispricings early by checking stocks our models flag as 48 high quality undervalued stocks.
• Lock in steadier income potential by reviewing companies identified as 10 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.